AstraZeneca’s Shares Have Fallen, but Is 14.6x Forward Earnings a Buying Opportunity?

AstraZeneca PLC (NYSE:AZN) is lagging the broader market this year so far, with shares declining by over 8%. The ...

AstraZeneca says FDA approves drug for rare kidney disease in adults

Oct 21 (Reuters) - AstraZeneca said on Wednesday the US Food and Drug Administration granted accelerated approval for its treatment for adults with immunoglobulin A nephropathy, a rare kidney disease ...
Crypto Briefing

AstraZeneca signs AI drug discovery deal with insitro worth up to $1.86 billion

AstraZeneca partners with insitro on an AI drug discovery deal worth up to $1.86 billion targeting fatty liver disease and ...

Jefferies puts AstraZeneca kidney drug trial success odds at 59%

Jefferies, the investment bank, estimates a 59% probability that AstraZeneca PLC (LSE:AZN, NYSE:AZN)’s zibotentan succeeds in ...

AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial

Oct 20 () - Amgen and AstraZeneca said on Tuesday their asthma drug helped reduce swallowing difficulties and achieved ...
BioSpace

AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitro

AstraZeneca will tap AI-focused insitro to find new targets for metabolic dysfunction-associated steatohepatitis and ...
Seeking Alpha

Why AstraZeneca May Be 2025's Most Underrated Pharma Stock

In 2025, AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises. So, revenue from Enhertu, which is a highly effective ...
CNBC on MSN

AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment

Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in Cambridge, Massachusetts.

AstraZeneca (AZN) Adds Oncology Catalysts. Is the Pipeline Worth Its Earnings Multiple?

Several Oncology Catalysts, One Earnings Question AstraZeneca PLC (NYSE:AZN) enters the3-27 European Society for Medical ...
Seeking Alpha

AstraZeneca's Growth Potential: 6 Reasons For A Buy Rating

AstraZeneca (AZN) is one of the biggest players in the healthcare sector, whose medicines save the lives of tens of thousands of people every year. In this article, I will share six reasons why I ...